natgillin/translations-raw huggingface dataset:
Toremifen binder sig specifikt til østrogenreceptorer, kompetitivt med estradiol, og hæmmer den østrogeninducerede stimulation af DNA syntesen og cellereplikationen.
Toremifene binds specifically to estrogen receptors, competitively with oestradiol, and inhibits estrogen- induced stimulation of DNA synthesis and cell replication.
Toremifen bør anvendes med forsigtighed hos patienter med nedsat leverfunktion (se pkt.
Toremifene should be used cautiously in patients with liver impairment (see section 5.2).
Toremifen er beregnet til postmenopausale kvinder.
Toremifene is recommended for postmenopausal patients.
Toremifen har en artsspecifik østrogen- lignende effekt hos mus og forårsager lignende tumorer.
Toremifene has a species-specific estrogen-like effect in mice and causes similar tumours.
Toremifen metaboliseres i udstrakt grad.
Toremifene is extensively metabolised.
Torisel 30 mg koncentrat og solvens til infusionsvæske, opløsning
Torisel 30 mg concentrate and diluents for solution for infusion
Torisel 30 mg koncentrat og solvens til infusionsvæske, opløsning.
Torisel 30 mg concentrate and diluent for solution for infusion
Torisel 30 mg koncentrat skal fortyndes med 1,8 ml solvens før injektion i natriumchlorid 9 mg/ml (0,9%) injektionsvæske.
Torisel 30 mg concentrate must be diluted with 1.8 ml of withdrawn diluent before administration in sodium chloride 9 mg/ml (0.9%) solution for injection.
Torisel 30 mg koncentrat skal fortyndes med den medfølgende solvens, før det blandes med natriumchlorid-infusionsvæske.
Torisel 30 mg concentrate must be diluted with the supplied diluent before administration in sodium chloride infusion.
Torisel 30 mg koncentrat skal først fortyndes med 1,8 ml af fortyndingsmidlet for at opnå en koncentration på 10 mg/ml før injektion i natriumchlorid 9 mg/ml (0,9%)-injektionsvæske (se fortyndingsvejledningen sidst i indlægssedlen).
Torisel 30 mg concentrate must first be diluted with 1.8 ml of withdrawn diluent to achieve a concentration of 10 mg/ml before administration in sodium chloride 9 mg/ml (0.9%) solution for injection (see dilution instructions at the end of the package leaflet).
Torisel 30 mg koncentrat:
Torisel 30 mg concentrate
Torisel anbefales ikke til patienter med kappecellelymfom, som har moderat til svær leversygdom.
Torisel is not recommended in patients with mantle cell lymphoma who have moderate or severe problems with their liver.
Torisel anvendes til behandling af voksne med følgende kræftformer:
Torisel is used to treat patients with the following types of cancer:
Torisel anvendes til voksne, når lymfomet er kommet tilbage efter tidligere behandling, eller ikke har reageret på andre behandlinger.
Torisel is used in adults when the lymphoma has come back after previous treatment or has not responded to other treatments.
Torisel er et koncentrat og fortyndingsmiddel, der blandes til en opløsning til infusion (dråbetilførsel i en vene).
Torisel is a concentrate and diluent that are made up into a solution for infusion (drip into a vein).
Torisel er et koncentrat til infusion leveret sammen med et fortyndingsmiddel.
Torisel is a concentrate for infusion supplied with a diluent.
Torisel er ikke blevet undersøgt hos gravide kvinder, og det må ikke anvendes under graviditet.
Torisel has not been studied in pregnant women, and it must not be used during pregnancy.
Torisel er ikke undersøgt hos patienter i hæmodialyse.
Torisel has not been studied in patients undergoing haemodialysis.
Torisel gives som en infusion, der varer 30 til 60 minutter.
Torisel is given as an infusion lasting 30 to 60 minutes.
Torisel har ingen kendt indflydelse på arbejdssikkerheden eller evnen til at færdes sikkert i trafikken.
Torisel has no known influence on the ability to drive and use machines.
Torisel indeholder, når det er fortyndet, polysorbat 80, der øger ekstraktionsgraden af DEHP fra PVC.
Torisel, when diluted, contains polysorbate 80, which is known to increase the rate of DEHP extraction from PVC.
Torisel indeholder, når det er fortyndet, polysorbat 80, som er kendt for at øge graden af ekstraktion af di-(2-ethylhexyl)phthalat (DEHP) fra polyvinylchlorid (PVC).
Torisel, when diluted, contains polysorbate 80, which is known to increase the rate of di-(2-ethylhexyl) phthalate (DEHP) extraction from polyvinyl chloride (PVC).
Torisel infunderes i løbet af en 30- til 60-minutters periode en gang om ugen.
Torisel is infused over a 30- to 60-minute period once a week.
Torisel kan forårsage hævelse af lungerne, som giver hoste og vejrtrækningsbesvær.
Torisel may cause non-specific interstitial pneumonitis.
Torisel kan få blodsukkeret til at stige og forværre diabetes mellitus.
Torisel may increase blood glucose levels and worsen diabetes mellitus.
Torisel koncentrat og solvens skal inspiceres visuelt for partikler og misfarvning inden administration.
The concentrate-diluent mixture should be inspected visually for particulate matter and discolouration.
Torisel koncentrat og solvens skal inspiceres visuelt for partikler og misfarvning inden administration.
Torisel concentrate and diluent should be inspected visually for particulate matter and discolouration prior to administration.
Torisel må ikke anvendes til personer, som er overfølsomme (allergiske) over for temsirolimus, over for dets metabolitter (de stoffer, det nedbrydes til), herunder sirolimus (et lægemiddel, der anvendes til at forebygge afstødning af transplanterede nyrer), over for polysorbat 80 eller over for andre af lægemidlets indholdsstoffer.
Torisel must not be used in people who are hypersensitive (allergic) to temsirolimus, to its metabolites (the substances that it is broken down into) including sirolimus (a medicine used to prevent rejection of transplanted kidneys), to polysorbate 80 or to any of the other ingredients of the medicine.
Torisel påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj eller betjene maskiner.
Torisel has no known influence on the ability to drive and use machines based on the evidence available.
Torisel skal gives som en intravenøs infusion.
Torisel must be administered by intravenous infusion.
Torisel skal indgives under overvågning af en læge, der har erfaring i brug af antineoplastiske lægemidler.
Torisel must be administered under the supervision of a physician experienced in the use of antineoplastic medicinal products.
Torisel var mere effektivt end sammenligningsbehandlingerne.
Torisel was more effective than the comparator treatments.
Torisels sikkerhed og effekt ved behandling af fremskredent renalcellekarcinom blev undersøgt i følgende to randomiserede kliniske studie:
The safety and efficacy of Torisel in the treatment of advanced renal cell carcinoma were studied in the following two randomised clinical trials:
Torre Realia, Plaza de Europa, 41-43 08908 L’Hospitalet de Llobregat Barcelona
Torre Realia, Plaza de Europa, 41-43 08908 L‟Hospitalet de Llobregat Barcelona
Torsades de
Torsade de pointes
Torsades de pointes er set hos <0,1% af patienterne, der har fået sunitinib.
Torsade de pointes has been observed in <0.1% of sunitinib-exposed patients.
torsades de pointes kan indgivelse
de pointes, administration of
Torsades de pointes og ventrikulær takykardi er indberettet som ikke almindelige bivirkninger hos patienter, der fik indgivet vandetanib 300 mg dagligt.
Torsades de pointes and ventricular tachycardia have been uncommonly reported in patients administered vandetanib 300 mg daily.
torsades de pointes, komplet AV-blok, grenblok, nodal arytmi
torsades de pointes, atrioventricular block complete, bundle branch block, nodal rhythm
Torsdag + søndag
Thursday + Sunday
torticollis (forværring fra baseline), dysgeusi
torticollis (worsening from baseline), taste perversion
Tosidet 95 % CI b
Two sided 95% CI b
Total
(0.04)
Total
(0.43)
Total (0-120 timer)
Overall (0-120 hours)
Total (n=77)
(n=27)
Total AKS
All ACS
Total AKS population: Sammenlignet med clopidogrel viste Efient større effekt i reduktion af det primære sammensatte endepunkt såvel som det præspecificerede sekundære endepunkt, inklusive stenttrombose (se tabel 3).
All ACS population: Efient showed superior efficacy compared to clopidogrel in reducing the primary composite outcome events as well as the pre-specified secondary outcome events, including stent thrombosis (see Table 3).
Total aktivitet
Total Activity.
Total aktivitet: MBq Totalt volumen: ml
Total activity: MBq Total volume: mL
Total alopeci relateret/muligvis relateret til administration af topotecan sås hos 9 % af patienterne, og udtalt alopeci relateret/muligvis relateret til administration af topotecan sås hos 11 % af patienterne.
Complete alopecia related/possibly related to topotecan administration was observed in 9 % of patients and partial alopecia related/possibly related to topotecan administration in 11 % of patients.
Total antal behandlede patienter (N)
Total patients treated (N)
Total arsen akkumuleres hovedsagligt i lever, nyre og hjerte og i mindre grad i lunge, hår og negle.
Total arsenic accumulates mainly in the liver, kidney, and heart and, to a lesser extent, in the lung, hair, and nails.
Total AUC (IE*·t/dl)
Total AUC (IU*·h/dl)
Total BASP-progression b
Total ALP progression c
Total behandling af kroppens overflade bør ikke overstige et areal som svarer til f.eks. behandling af begge flanker fra ryggen til yveret, og som inkluderer skuldre og hofter.
Total body surface treated should not exceed a surface corresponding for example to a treatment of two flanks from the spine to the mammary chains including the shoulders and the thighs.
Total behandlingssucces
Overall Treatment Success
Total behandlingssucces efter den neutropene status
Overall Treatment Success by Neutropenic Status
Total behandlingssucces i per-protokol-sæt, forsøg med invasiv candidiasis
Overall Treatment Success in the Per Protocol Set, Invasive Candidiasis Study
Total bilirubin = 1,5 ULN
Total bilirubin: = 1.5 ULN
Total bilirubin > 1,5-3,0 ULN ASAT: alt
Total bilirubin: >1.5–3.0 ULN AST: any
Total bilirubin > 3-10 ULN ASAT: alt
Total bilirubin: >3–10 ULN AST: any
Total bilirubin: = 1,5 ULN
Total bilirubin: = 1.5 ULN
Total bilirubin: > 3-10 ULN AST: alt
Total bilirubin: > 3-10 ULN AST: any
Total bilirubin: >1,5-3,0 ULN- ASAT: alt
Total bilirubin: >1.5-3.0 ULN AST: any
Total bilirubin: >1,5-3,0 ULN- ASAT: alt
Total bilirubin: >1.5–3.0 ULN AST: any
Total bilirubin: >1,5–3,0 ULN ASAT: alt
Total bilirubin: >1.5–3.0 ULN AST: any
Total bilirubin: >310 ULN- ASAT: alt
Total bilirubin: >3-10 ULN
Total bilirubin: >310 ULN- ASAT: alt
Total bilirubin: >3-10 ULN AST: any
Total bilirubin: >310 ULN- ASAT: alt
Total bilirubin: >3–10 ULN AST: any
Total bilirubin: >3–10 ULN ASAT: alt
Total bilirubin: >3–10 ULN AST: any
Total body- og nyre-clearance er henholdsvis 157-176 og 3-
The total body and renal clearance are 157
Total clearance (ml/(timer*kg)
Total clearance
Total clearance er cirka 2 l/t, og mindre end 5 % af dosis udskilles i urinen.
Total clearance is around 2 l/h, and less than 5% of the dose is excreted in the urine.
Total clearance for levodopa ligger i området 0,55-1,38 l/kg/time og for entacapon i området 0,70 l/kg/time.
Total clearance for levodopa is in the range of 0.55-1.38 l/kg/h and for entacapone is in the range of
Total clearance for levodopa ligger i området 0,55-1,38 liter/kg/time og for entacapon i området 0,70 liter/kg/time.
Total clearance for levodopa is in the range of 0.55-1.38 l/kg/h and for entacapone is in the range of
Total daglig dosis pregabalin *
Total pregabalin daily dose
Total daglig ribavirindosis (mg)
Total daily ribavirin dose (mg)
Total dosis
Total dose
Total dosis af påkrævet FSH (antal FSH 75 IE ampuller)
Total dose of FSH required (number of FSH 75 IU ampoules)
Total dosis meloxicam (mg)*
Total dose meloxicam (mg)
Total dødelighed
All-cause mortality
Total EDTMP (SOM EDTMP·H2O)
Total EDTMP (as EDTMP.H2O)
Total eller udtalt alopeci blev observeret hos 30 % af patienterne, og partiel alopeci hos 15 % af patienterne.
Total or pronounced alopecia was observed in 30 % of patients and partial alopecia in 15 % of patients.
Total elotuzumab-dosis i mg = patientens vægt i kg x 10.
The total elotuzumab dose in mg = the patient’s weight in kg x 10.
Total fikseret fleksionskontraktur og ledbevægelighed efter administration af to samtidige injektioner af Xiapex 0,58 mg i den samme hånd, mITT-population, studie AUX-CC-867 (første behandlingscyklus)
Total fixed flexion contracture and range of motion following administration of two concurrent injections of Xiapex 0.58 mg in the same hand, mITT population, study AUX- CC-867 (first treatment cycle)
Total fortyndingsvolumen
Total diluted volume
Total infusions- volumenB
Total infusion volume B
Total infusions- volumenB
Total infusion volumeB
total kolesterol
total cholesterol
Total kolesterol (mg/dl)
Total cholesterol. (mg/dL)
Total kolesterol (mmol/l)
TC (mmol/L)
Total krops- og nyreclearance er henholdsvis 157-176 og 3- 3,5 ml/min.
The total body and renal clearance are 157-176 and 3-3.5 ml/min, respectively.
Total legemsclearance er 5,04 ± 2,5 l/t uafhængigt af dosis og uanset køn, alder, race og legemsvægt.
The total body clearance is 5.04 ± 2.5 l/h, independent of dose, and unaffected by gender, age, race, and body weight.
Total legemsclearance er 5,04 ± 2,5 l/time uafhængigt af dosis og uanset køn, alder, race og legemsvægt.
The total body clearance is 5.04 ± 2.5 l/h, independent of dose, and unaffected by gender, age, race or body weight.
Total legemsclearance er 5,04±2,5 l/t uafhængigt af dosis og uanset køn, alder, race og legemsvægt.
The total body clearance is 5.04 ± 2.5 l/h, independent of dose, and unaffected by gender, age, race, and body weight.
Total legemsmasse
Total Body
Total medianoverlevelse var også signifikant længere til fordel for TPF-armen (median for total overlevelse: 18,6 mod
Median overall survival was also significantly longer in favour of the TPF arm compared to the PF arm (median OS: 18.6 vs.
Total mortalitet
All-cause mortality
Total mængde opløsning (ml)
Total Solution Volume (ml)
Total mængde Rienso, der skal administreres mg jern (antal hætteglas)
Total Amount of Rienso to Administer mg of Iron (Number of vials)
Total oral clearance (CL/F) er 34-62 l/time.
Total oral clearance (CL/F) was 34-62 l/h.
Total overlevelse
positive
Total overlevelse (Primær endepunkt)
Overall survival (Primary endpoint)
Total overlevelsesrate på specifikke tidspunkter er vist grafisk i Figur 4.
The OS rate by specific timepoint is displayed graphically in Figure 4.
Total overlevelsesrate var konsekvent højere hos dasatinib-behandlede patienter, som opnåede BCR-ABL-niveau ≤ 10% ved måned 3, sammenlignet med dem, der ikke gjorde.
Rate of OS was consistently higher in dasatinib treated patients who achieved BCR-ABL level ≤ 10% at 3 months than those who did not.
Total parenteral ernæring (TPN) behøver ikke at blive afbrudt, når der udskrives Voriconazole Hospira, men de skal infunderes i hver sin dropslange.
Total parenteral nutrition (TPN) need not be discontinued when prescribed with Voriconazole Hospira, but does need to be infused through a separate line.
Total plasmaclearance af rosiglitazon er omkring 3 l/time, og den endelige halveringstid er cirka 3-4 timer.
Total plasma clearance of rosiglitazone is around 3 l/h and the terminal elimination half-life of rosiglitazone is approximately 3-4 h.
Total plasmaclearance og nyreclearance er henholdsvis 1,2 ml x min-1 x kg-1 og 0,1 ml x min-1 x kg-1.
The total plasma clearance and the renal clearance are 1.2 ml x min-1 x kg-1 and 0.1 ml x min-1 x kg-1, respectively.
Total radioaktivitet i begge stykker af ITLC-SG MAM strippen
Total radioactivity in both pieces of ITLC-SG MAM strip
Total radioaktivitet i begge stykker af ITLC-SG MNO strippen
Total radioactivity in both pieces of ITLC-SG SSCS Strip
Total respons rate (%)
Overall response rate (%):
Total responsgrad (%)
Complete Response Rate (%)
Total responshyppighed var 59,3 % (95 % CI : 52,8 – 65,9) i AT armen i forhold til 46,5 % (95 % CI : 39,8 – 53,2) i AC armen.
Overall response rate (ORR) was significantly higher in the AT arm versus AC arm, p=0.009. The ORR was 59.3% (95% CI : 52.8 - 65.9) in AT arm versus 46.5% (95% CI : 39.8 - 53.2) in AC arm.
Total scored (van der Heijde- modified Sharp score)
Change from baseline in total van der Heijde-modified Sharp scoreb
Total scored (van der Heijde- modified Sharp score)
Total scored (van der Heijde-modified Sharp score)
Total Sharp
Total Sharp score
Total Sharp-score
Total Sharp score
Total studiepopulation
Total Study Population
Total TC 243
Total TC
Total testosteron (ng/dl)
Total testosterone (ng/dl)
Total volumen af Removab- koncentrat til injektionsvæske, opløsning
Total volume of Removab concentrate for solution for infusion
Total VTE/alle dødsårsager
Total VTE/all-cause death
Total vægt af produkt i gram = total legemsvægt i kg (for de svin, der skal behandles) x 5/625.
Total weight of product in grams = total bodyweight of pigs to be treated in kg x 5 / 625.
Total-
Total
Total-bilirubin = 1,5 ULN
Total bilirubin: = 1.5 ULN
Total-bilirubin > 5 x ULN
Total bilirubin > 5 x ULN
Total-bilirubin skal være  1,5 gange den normale øvre grænseværdi.
The total bilirubin should be ≤ 1.5 times upper limit of normal.
Total-bilirubin skal være  1,5 gange den normale øvre grænseværdi.
The total bilirubin should be ≤ 1.5-times upper limit of normal.
Total-bilirubin: = 1,5 ULN
Total bilirubin: = 1.5 ULN
Total-bilirubin: >1,5–3,0 ULN ASAT: alt
Total bilirubin: >1.5–3.0 ULN AST: any
Total-bilirubin: >3–10 ULN ASAT: alt
Total bilirubin: >3–10 ULN AST: any
Total-clearance af Aripiprazoleer 0,7 ml/min/kg, primært hepatisk.
The total body clearance of aripiprazole is 0.7 ml/min/kg, which is primarily hepatic.
Totale AKS
All ACS
Totale antal kg fisk, der skal behandles
Total kg of fish to be injected
Totale lymfocyttal <0,8x109 celler/l ([Common Terminology Criteria for Adverse Events – CTCAE] grad 2; mindst en måling) forekom hos 4% af placebopatienterne og hos 5% af de Zinbryta-behandlede patienter i SELECT-studiet, og hos 9% af patienterne behandlet med interferon beta-1a (intramuskulært) og hos 8% af de Zinbryta-behandlede patienter i DECIDE-studiet.
Total lymphocyte counts <0.8x109 cells/L ([Common Terminology Criteria for Adverse Events – CTCAE] Grade 2; at least one measurement) occurred in 4% of placebo-treated and 5% of Zinbryta-treated patients in the SELECT study, and 9% of the interferon beta-1a (intramuscular)-treated and 8% of Zinbryta-treated patients in the DECIDE study.
Totale metaller*  50 ppm
Total metals*  50 ppm
totale objektive responsrater i den totale randomiserede population var (investigators vurdering) 25,7 % (capecitabin) vs.
The overall objective response rates in the all-randomised population (investigator assessment) were 25.7% (capecitabine) vs.
totalkolesterol apolipoprotein-B, et protein, der transporterer “skadeligt kolesterol” i blodet triglycerider (fedt, der transporteres i blodet)
total cholesterol apolipoprotein-B, a protein that carries “bad cholesterol” in the blood triglycerides (fat carried in the blood)
Totalt (0-120 timer)
Overall (0-120 hours)
Totalt 225 patienter blev behandlet med Ilaris 150 mg subkutant, og 229 patienter blev behandlet med intramuskulært triamcinolonacetonid (TA) 40 mg ved studiestart og efterfølgende ved hvert nyt anfald.
A total of 225 patients were treated with subcutaneous Ilaris 150 mg and 229 patients were treated with intramuscular triamcinolone acetonide (TA) 40 mg at study entry, and when experiencing a new attack thereafter.
Totalt aktive HMG Co-A
Total active HMG Co-A reductase inhibitors:
Totalt antal alvorlige hypoglykæmiske episoder under graviditet (per patientår)
Overall number of major hypoglycemia episodes during pregnancy (per patient year)
Totalt antal patienter i studiet
Total patients studied
Totalt antal patienter med bivirkninger
Total patients with any AE
Totalt antal patienter med prædefinerede bivirkninger
Total patients with pre-defined AE(s)
Totalt blev 350 patienter randomiseret (randomiseringsratio 1:1).
A total of 350 patients were randomized (randomization ratio 1:1).
Totalt blev 6068 patienter randomiseret 1:1 til enten placebo eller lixisenatid 20 µg (efter en start dosering af 10 µg i løbet af de første 2 uger).
Overall, 6068 patients were randomized 1:1 to either placebo or lixisenatide 20 mcg (following a starting dose of 10 mcg during the first 2 weeks).
Totalt celleantal: x10X
Total cell number: x10X
Totalt kolesterol består hovedsageligt af "dårligt" (LDL) og "godt" (HDL) kolesterol.
Your total cholesterol is made up mainly of ‘bad’ (LDL) and ‘good’ (HDL) cholesterol.
Totalt leveret lægemiddel [mg±SD]
Total Drug Delivered [mg±SD]
Totalt organisk kulstof (f.eks. organiske chelatdannere) Under kvantiseringsgrænsen* Restprodukter (f.eks. ammoniak, nitrat) Under kvantiseringsgrænsen*
Total organic carbon (e.g. organic chelators) Below limit of quantitation* Process residuals (e.g. ammonia, nitrate) Below limit of quantitation
Totalt rekonstitueret volu- men i hætteglas
Total Lymphoseek vial reconstitution volume
Totalt set rapporterede 99 ud af 8.956 patienter i vildagliptin-gruppen en hændelse versus 91 ud af 6.061 patienter i sammenligningsgruppen.
In total, 99 out of 8956 patients reported an event in the vildagliptin group vs 91 out of 6061 patients in the comparator group.
Totalt set viste sammenligningen af AUC'er mellem Dag 1 og Dag 7 en tidsuafhængighed af farmakokinetik, hvilket tydede på linearitet ved det dosisniveau, som blev administreret i denne undersøgelse.
Overall, the comparison of AUCs between Day 1 and Day 7 showed a time independence of pharmacokinetics, indicating linearity at the dose level administered in this study.
Totalt volumen, der skal injiceres
Total volume to be injected
Totalt volumen, som skal
Total volume to compound
Totalt§
Overall§
Totalt§ 72,9 74,6 -1,7 (-5,3; 2,0)
Overall§ 72.9 74.6 -1.7 (-5.3, 2.0)
Toujeo 100 enheder/ ml injektion, opløsning i cylinderampul er en klar og farveløs opløsning.
Toujeo 100 units/ml solution for injection in a cartridge is a clear and colourless solution.
Toujeo 100 enheder/ml injektionsvæske, opløsning, i cylinderampul
Toujeo 100 units/ml solution for injection in a cartridge
Toujeo 100 enheder/ml injektionsvæske, opløsning, i cylinderampul til OptiClik
Toujeo 100 units/ml solution for injection in a cartridge for OptiClik
Toujeo 100 enheder/ml injektionsvæske, opløsning, i et hætteglas Toujeo 100 enheder/ml injektionsvæske, opløsning, i en cylinderampul
Toujeo 100 units/ml solution for injection in a vial Toujeo 100 units/ml solution for injection in a cartridge
Toujeo 100 enheder/ml injektionsvæske, opløsning, i hætteglas
Toujeo 100 units/ml solution for injection in a vial
Toujeo 100 enheder/ml injektionvæske, opløsning i hætteglas er en klar, farveløs og vandlignende opløsning.
Toujeo 100 units/ml solution for injection in a vial is a clear colourless and waterlike solution.
Toujeo 100 enheder/ml injetionsvæske, opløsning i cylinderampul til OptiClik er en klar fraveløs opløsning.
Toujeo 100 units/ml solution for injection in a cartridge for OptiClik is a clear, colourless solution.
Toujeo 100 enheder/ml medførte et fald i HbA1c-niveauet, hvilket tyder på, at blodsukkeret var blevet holdt under kontrol på et niveau, der svarede til det, der var observeret for andet humant insulin.
Toujeo 100 units/ml led to a decrease in the level of HbA1c, indicating that blood glucose levels had been controlled to a similar level to that seen with human insulin.
Toujeo 100 enheder/ml, injektionsvæske, opløsning i en cylinderampul Insulin glargin
Toujeo 100 units/ml solution for injection in a cartridge Insulin glargine
Toujeo 100 enheder/ml, injektionsvæske, opløsning i en cylinderampul til OptiClik Insulin glargin
Toujeo 100 units/ml solution for injection in a cartridge for OptiClik Insulin glargine
Toujeo 100 enheder/ml, injektionsvæske, opløsning i et hætteglas Insulin glargin
Toujeo 100 units/ml solution for injection in a vial Insulin glargine
Toujeo 100 enheder/ml, injektionsvæske, opløsning Insulin glargin
Toujeo 100 units/ml solution for injection Insulin glargine
Toujeo 100 enheder/ml,injektionsvæske, opløsning Insulin glargin
Toujeo 100 units/ml solution for injection Insulin glargine